Immunotherapy
Best Practices in Lung Cancer – November 2018 Vol 9 | November 29, 2018
The medical management landscape for non–small cell lung cancer (NSCLC) has been changing with the rapidity of the seasons. Long gone is the day when all are treated equally.
April 2018 Vol 9, No 4 | April 10, 2018
As single-agent immunotherapies continue to show promising results, the challenge is now to determine which combination regimens with immunotherapies can improve outcomes.
February 2018 Vol 9, No 2 | February 15, 2018
As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation is used to treat painful lesions, brain metastases, or isolated progression.
February 2018 Vol 9, No 2 | February 15, 2018
Immunotherapy has changed the landscape of oncology, particularly in advanced metastatic disease, where the chance of prolonged remission is now measured in years or even into the early decades in some cancers.
November 2017 Vol 8, No 11 | November 14, 2017
Accessing chimeric antigen receptor (CAR) T-cell clinical trials for relapsed and refractory B-cell acute lymphoblastic leukemia (ALL) is challenging for pediatric patients who have experienced a relapse of B-cell ALL or have been refractory to standard therapy.
September 2017 Vol 8, No 9 | August 31, 2017
As immune checkpoint inhibitors gain traction for the treatment of a variety of cancers, it is important to be aware of all the potential side effects that can occur.
August 2017 Vol 8, No 8 | August 3, 2017
In the longest follow-up on single-agent nivolumab to date, 5-year overall survival (OS) was 16% in patients with advanced non–small cell lung cancer (NSCLC) in updated results from a phase 1b dose-ranging study (CA209-003).
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
One of the many responsibilities of a navigator is to facilitate patient education—it is therefore imperative that we educate ourselves on new treatments, distill the information into lay terms, and use that information to effectively educate our patients.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
A new study has shown that combination immunotherapy can yield significant clinical benefits—even in heavily pretreated populations.
Best Practices in Immunotherapy – June/July 2017 Vol 8 | July 19, 2017
The production of antibodies is the immune system’s way of waging an attack on something threatening. Monoclonal antibodies can be designed as immunotherapies that will attach to specific proteins on cancer cells, flag them for recognition by the immune system, and thus help decimate them.
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512